Advanced Enzyme
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Management at Advanced Enzyme Technologies has expressed a confident outlook, emphasizing a resilient and diversified business model that has effectively navigated regional disruptions. Key developments include a strategic focus on AI-driven R&D and advanced fermentation technologies, which are expected to enhance innovation and market penetration. Despite facing external challenges such as tariff-related issues in the Americas and rising logistics costs, management is prioritizing operational efficiency and new product launches. Vista's financial outlook reflects a moderation in revenue growth, with expectations of stable profit margins supported by a conservatively financed balance sheet. The anticipated European approval for new products and expansion into high-potential geographies, particularly in India, are significant growth catalysts. However, geopolitical tensions and inflationary pressures in the U.S. market pose risks that could impact margins and working capital. Overall, the company is well-positioned to leverage its strengths in a growing industry, with a projected 12-month target price of approximately 346.50, indicating a modest expected upside. Over the next 12-24 months, opportunities include product innovation and geographic expansion, while headwinds may arise from input cost pressures and supply chain uncertainties
Why We Like This Stock
- Management's focus on AI-driven R&D and advanced fermentation technologies is expected to enhance innovation and market penetration
- Anticipated European product approvals and expansion into high-potential geographies present significant growth opportunities
- The company's conservatively financed balance sheet supports financial stability amid external challenges
Things To Watch Out For
- Geopolitical tensions are driving up input costs, which may pressure margins in a competitive market
- Inflationary pressures in the U.S. could impact discretionary spending and overall market performance
- Supply chain uncertainties necessitate inventory build-up, affecting working capital and operational efficiency
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 624 | 637 | 746 | 739 | 806 |
| Profit Before Tax (Cr.) | 203 | 187 | 222 | 204 | 227 |
| PBT Margin | 32.6% | 29.3% | 2971.0% | 27.6% | 28.1% |
| Net Profit (Cr.) | 143 | 138 | 168 | 155 | 167 |
| Earnings Per Share | 12.4 | 12.1 | 14.6 | 13.4 | 14.9 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis. It also provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is headquartered in Thane, India.